TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease.
We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations.
We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations.
Location: United Kingdom, Scotland, Holytown
Employees: 51-200
Founded date: 2014
Investors 3
Mentions in press and media 5
| Date | Title | Description |
| 28.10.2022 | Two Aurinia execs are out — and CRISPR’s operations chief isn't far behind; Biogen MS leader jumps to Eli Lilly partner | Robert Huizinga → According to an SEC filing, Aurinia’s EVP of research Robert Huizinga and CMO Neil Solomons are both walking away by Halloween, and while no explanations are given, details of their severance packages were... |
| 17.09.2020 | Immune system ‘bully boys’ square up to coronavirus crisis | Scalable, affordable, effective. Read about TC Biopharm’s stunning progress in the Financial Times here. “After winning approval from the UK’s Medicines and Healthcare Products Regulatory Agency to treat Covid-19 patients, the privately he... |
| 17.09.2020 | Immune system ‘bully boys’ square up to coronavirus crisis | Scalable, affordable, effective. Read about TC Biopharm’s stunning progress in the Financial Times here. “After winning approval from the UK’s Medicines and Healthcare Products Regulatory Agency to treat Covid-19 patients, the privately he... |
| 12.12.2017 | bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy | – Deal combines TC BioPharm’s leading gamma delta T Cell capabilities with bluebird’s proven expertise in all stages of CAR T and gene therapy product development to discover and develop next-generation liquid and solid tumor product candid... |
| 12.12.2017 | bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy | – Deal combines TC BioPharm’s leading gamma delta T Cell capabilities with bluebird’s proven expertise in all stages of CAR T and gene therapy product development to discover and develop next-generation liquid and solid tumor product candid... |